ZFX

Across TCGA pan-cancer cohorts, ZFX Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ZFX data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZFX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZFX expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where ZFX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.021	0.751	<.001	48	view →
UCEC	DFS	Median	All	0.968	0.612	.002	36	view →
LUAD	OS	Median	II,III,IV	0.152	0.712	<.001	30	view →
LIHC	OS	Median	All	0.226	0.773	.008	12	view →
SKCM	OS	Median	III,IV	0.204	0.729	<.001	9	view →
KIRC	OS	Median	All	0.194	0.630	.018	6	view →
SARC	DFS	Median	All	0.037	0.632	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
GBM	OS	Median	All	0.104	0.415	.024	3	view →
STAD	DFS	Median	III,IV	0.279	0.612	.047	3	view →
CESC	DFS	Median	II,III,IV	0.472	0.791	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ZFX–HNSC (OS)

Open the HNSC breakdown →